Patent Law

Teva Reveals ?Man on the Street? Wants Lower Healthcare Costs. Surprised?

By Stephen Albainy-Jenei

Teva Pharmaceuticals USA, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., is making a full-court press on getting the word out on the need for follow-on biologics.  In its “Year of Affordable Healthcare” campaign, Teva is putting put together videos to argue for generics, just as the White House is making its position known on the need for biogenerics (read: need for lower costs).

The program commemorates the 25th anniversary of the Waxman-Hatch Act which created the modern generic drugs industry and features videos that ask the “man on the street” in Washington, D.C. what they think about healthcare in the U.S.   It wouldn’t take the Amazing Kreskin to guess that people want lower healthcare costs.  It’s a thorny issue with some biotech therapies costing as much as $500,000 annually.

See more here.

Related posts:

1. Jogging Pills Urge You to Compare Drug Costs Consumer R
2. Bill Introduced to Prohibit the Marketing of Authorized Generic Drugs The 1984 H
3. Book Review Monday: The Generic Challenge “Who

Related posts brought to you by Yet Another Related Posts Plugin.

Full post as published by Patent Baristas on June 30, 2009 (boomark / email).